Aptamer-Peptide Conjugates as _targeted Chemosensitizers for Breast Cancer Treatment
- PMID: 33306339
- DOI: 10.1021/acsami.0c18282
Aptamer-Peptide Conjugates as _targeted Chemosensitizers for Breast Cancer Treatment
Abstract
High levels of heat shock protein 70 (HSP70) in tumors are commonly associated with poor prognosis, enhanced doxorubicin (DOX)-induced cardiotoxicity, and even drug resistance in DOX-related cancer chemotherapy. Several peptides possess remarkable protein inhibition and chemosensitization effects, which are attributed to their specific _targeting ability against HSP70. However, the inherent poor cell penetration capacity considerably restricts the biomedical applications of these peptides. We herein describe the design and development of anti-MUC1 aptamer-peptide conjugates (ApPCs) as _targeted chemosensitizers to overcome the above-mentioned issues. Moreover, DOX could be loaded on the ApPC to deliver the DOX-enclosed agent ApPC-DOX, which simultaneously acts as a _targeted chemosensitizer and anticancer agent for combating drug resistance in breast cancer therapy. This innovative, engineered biocompatible conjugate not only enhances the sensitivity of DOX-resistant cells but also alleviates cardiotoxicity of DOX in vivo, highlighting the success of this _targeted chemosensitizer strategy.
Keywords: HSP70; aptamer; cardiotoxicity; peptide; _targeted chemosensitizer; _targeted drug delivery.
Similar articles
-
Multifunctional aptamer-based nanoparticles for _targeted drug delivery to circumvent cancer resistance.Biomaterials. 2016 Jun;91:44-56. doi: 10.1016/j.biomaterials.2016.03.013. Epub 2016 Mar 10. Biomaterials. 2016. PMID: 26994877
-
Aptamer-drug conjugate: _targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.Int J Nanomedicine. 2018 Feb 5;13:763-776. doi: 10.2147/IJN.S149887. eCollection 2018. Int J Nanomedicine. 2018. PMID: 29440899 Free PMC article.
-
Using Peptide Aptamer _targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.Mol Pharm. 2017 Oct 2;14(10):3539-3549. doi: 10.1021/acs.molpharmaceut.7b00560. Epub 2017 Sep 7. Mol Pharm. 2017. PMID: 28880092
-
Molecular assembly of an aptamer-drug conjugate for _targeted drug delivery to tumor cells.Chembiochem. 2009 Mar 23;10(5):862-8. doi: 10.1002/cbic.200800805. Chembiochem. 2009. PMID: 19253922 Free PMC article.
-
Peptides as innovative strategies to combat drug resistance in cancer therapy.Drug Discov Today. 2024 Oct 10;29(12):104206. doi: 10.1016/j.drudis.2024.104206. Online ahead of print. Drug Discov Today. 2024. PMID: 39395530 Review.
Cited by
-
Recent Advances and Prospects of Nucleic Acid Therapeutics for Anti-Cancer Therapy.Molecules. 2024 Oct 7;29(19):4737. doi: 10.3390/molecules29194737. Molecules. 2024. PMID: 39407665 Free PMC article. Review.
-
Stimuli-responsive peptide assemblies: Design, self-assembly, modulation, and biomedical applications.Bioact Mater. 2024 Feb 2;35:181-207. doi: 10.1016/j.bioactmat.2024.01.023. eCollection 2024 May. Bioact Mater. 2024. PMID: 38327824 Free PMC article. Review.
-
The role of peptides in reversing chemoresistance of breast cancer: current facts and future prospects.Front Pharmacol. 2023 May 22;14:1188477. doi: 10.3389/fphar.2023.1188477. eCollection 2023. Front Pharmacol. 2023. PMID: 37284316 Free PMC article. Review.
-
DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors.Cancers (Basel). 2023 Apr 5;15(7):2151. doi: 10.3390/cancers15072151. Cancers (Basel). 2023. PMID: 37046816 Free PMC article. Review.
-
The Regioselective Conjugation of the 15-nt Thrombin Aptamer with an Optimized Tripeptide Sequence Greatly Increases the Anticoagulant Activity of the Aptamer.Pharmaceutics. 2023 Feb 10;15(2):604. doi: 10.3390/pharmaceutics15020604. Pharmaceutics. 2023. PMID: 36839926 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
